Enovis Corporation (NYSE:ENOV) is considered one of the best undervalued medical device stocks to buy now, with a Buy rating and $46.00 price target from Evercore ISI. Fiscal Q1 2025 results show net sales of $559 million, with an 8% growth reported and 9% rise on a comparable basis from last year.

Enovis Corporation (NYSE:ENOV) reported strong commercial momentum in fiscal Q1 2025, with Recon net sales growing 11% on a reported and comparable basis. The company demonstrated growth in new product introductions and execution in Prevention & Recovery, reflecting a 5% growth on a reported basis and 7% on a comparable basis.

Enovis Corporation (NYSE:ENOV) is a medical technology growth company focused on developing clinically differentiated solutions to improve patient outcomes. Operating through Prevention & Recovery and Reconstructive segments, the company continues to innovate in the medical device industry.

While Enovis Corporation (NYSE:ENOV) shows investment potential, other AI stocks may offer greater upside with less risk. For those seeking undervalued AI stocks, consider options that could benefit from current economic trends. Explore our free report on the best short-term AI stock for more information.

Read more at Yahoo Finance: Evercore ISI Maintains a Buy on Enovis Corporation (ENOV) With a $46 PT